Publications by authors named "L Diella"
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.
Curr Issues Mol Biol
December 2024
Article Synopsis
- Novel antimicrobial drugs, like cefiderocol, have been developed to tackle the rise of antimicrobial resistance, specifically against multidrug-resistant (MDR) Gram-negative bacilli (GNB).
- Cefiderocol, a unique siderophore cephalosporin, efficiently penetrates bacterial outer membranes, making it effective against various resistance strategies and offering a broad spectrum of action.
- Despite its effectiveness, recently identified cefiderocol-resistant strains highlight the need for new strategies in clinical practice to maintain its antibacterial efficacy.
Article Synopsis
- A recent court ruling in Italy set new rules for hospitals about how to prove they're taking care of patients so they don't get infections while in the hospital.
- The study looked at two groups of patients who had infections to see how well the court's rules worked compared to actual patient conditions, like if the infection was caused by a bad germ or poor treatment.
- Results showed that 84% of the patients in the court group had hospital-related infections, while only 46% in the other group did, suggesting the court's new rules might not always match real situations.
Background: The role of intravenous fosfomycin (iv-FOS) as a part of combination therapy for Gram-negative bacteria bloodstream infections (GNB-BSI) needs to be evaluated in clinical practice, as in vitro data show potential efficacy.
Methods: All consecutive patients with a GNB-BSI from 01 January 2021 to 01 April 2023 were included. Primary outcome was 30-day mortality.
Background: Mental health (MH) is extremely relevant when referring to people living with a chronic disease, such as people living with HIV (PLWH). In fact - although life expectancy and quality have increased since the advent of antiretroviral therapy (ART) - PLWH carry a high incidence of mental disorders, and this burden has been exacerbated during the COVID-19 pandemic. In this scenario, UNAIDS has set new objectives for 2025, such as the linkage of at least 90% of PLWH to people-centered, context-specific MH services.
View Article and Find Full Text PDFImmune checkpoint inhibitors (ICIs) represent the cornerstone of the current treatment of non-small cell lung cancer (NSCLC). However, the occurrence of concomitant infections might hamper success. All consecutive patients with advanced NSCLC who started ICIs as a first- or second-line therapy from January 1, 2017 to June 30, 2020 were retrospectively evaluated.
View Article and Find Full Text PDF